Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non–Small Cell Lung Cancer
Authors:
- 1 May 2017
- journal article
- case report
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (5) , e41-e43
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapyJournal of Diabetes Investigation, 2016
- Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 DiabetesThe Tohoku Journal of Experimental Medicine, 2016
- Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 DiabetesDiabetes Care, 2015
- Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 DiabetesDiabetes Care, 2015
- Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case reportCancer Immunology, Immunotherapy, 2015
- Precipitation of Autoimmune Diabetes With Anti-PD-1 ImmunotherapyDiabetes Care, 2015
- Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute‐onset Type 1 Diabetes Mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012)Journal of Diabetes Investigation, 2012